West Pharmaceutical Services (WST) has a solid position in the injectable-drug containment market with "sticky recurring revenue," and the stock price has dropped to an "attractive entry point" after underwhelming Q4 results and 2025 guidance, Deutsche Bank said Friday in a note.
The stock is currently trading close to pre-pandemic levels and is at the lower end of the range over the past five to 10 years, the note said. Deutsche Bank's base case suggests a 20% internal rate of return over two years with potential returns ranging from high single digits to mid-30% based on execution and exit conditions.
"The stock can re-rate as investors regain confidence in execution on the 2025 guidance and West's return to its long-range plan," the note said.
Deutsche Bank upgraded the stock to buy from hold and lowered its price target to $250 from $275.
West Pharmaceutical shares rose 11% in recent Friday trading.
Price: 221.74, Change: +22.62, Percent Change: +11.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.